ICER Report Presents Evidence-based Guidance to Support Integration of Behavioral Health into Primary Care

Boston, Mass., June 2, 2015 – The Institute for Clinical and Economic Review (ICER) has posted the final report Integrating Behavioral Health into Primary Care and its accompanying action guides and policy brief to the CTAF and CEPAC websites. The report evaluates the evidence on the comparative clinical effectiveness and value of efforts to integrate behavioral health into primary care settings as well as providing guidance on how to apply that evidence in the real world.

Read the full press release here. 

Read More

New Members of CEPAC Named for 2015

Boston, Mass., April 24, 2015 – The Institute for Clinical and Economic Review (ICER) has announced the new members of the 2015 New England Comparative Effectiveness Public Advisory Council (CEPAC). The 18 members of CEPAC represent a wide variety of backgrounds, specialties and perspectives, and come from all six New England states. CEPAC consists of practicing physicians and economists with experience in evaluating and using evidence in the practice of health care, as well as patient/public members with experience in health policy, patient advocacy and public health. Representatives of regional public and private payers are included as ex-officio members of CEPAC. Members of CEPAC are chosen based on their expertise in reviewing and applying medical evidence in a variety of contexts and are not selected based on their specific expertise in a given clinical area.

For a full listing of the 2015 CEPAC members, read the full press release here. 

Read More

Next CEPAC Meeting to Address Drug Therapies for High Cholesterol

The Institute for Clinical and Economic Review (ICER) announced that the next report and meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC) will address drug therapies for high cholesterol, including a review of an emerging class of drugs, PCSK9 inhibitors. The drugs have shown promising clinical outcomes in early trials, and the FDA is expected to make approval decisions on the PCSK9 inhibitors alirocumab (Regeneron/Sanofi) and evolocumab (Amgen) in late summer 2015.

ICER’s report will include a systematic review of the published evidence on these new treatment options relative to existing alternatives, and will also feature a calculation of a “value-based price benchmark” for PCSK9 inhibitors based on an analysis of comparative cost-effectiveness and potential short-term budget impact. It will serve as the basis for discussion at CEPAC’s next public meeting on October 27, 2015.

Read the full announcement here. Meeting registration is now open.

Read More